Pediatric products with overlapping age directions not inherent problem -- NDAC's Brass.
This article was originally published in The Tan Sheet
Executive Summary
PEDIATRIC OTCs OVERLAPPING AGE DIRECTIONS NOT INHERENT PROBLEM in the opinion of FDA Nonprescription Drugs Advisory Committee member Eric Brass, MD/PhD, Harbor UCLA Medical Center. Brass' comment came during NDAC's Sept. 18 meeting in Gaithersburg, Md. on whether safety problems or dosing errors result from an age overlap in the two- to three-year-old age group in labeling directions for the use of two different strengths of pediatric analgesic/antipyretic drugs: regular strength liquid and more concentrated drops. The directions for use for these products are not "intrinsically" a problem, Brass said, but there may be "problems relating to label comprehension," he added.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning